BSG and cancer: Basigin, also known as CD147 or EMMPRIN (extracellular matrix metalloproteinase inducer), is gradually being recognized as a cancer-associated biomarker, and significant clinical therapeutic progress has been made using anti-basigin monoclonal antibodies that target HCC [16, 17].